Pfizer Ltd

Information

Name

Pfizer Ltd

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

https://etendersni.gov.uk/epps

Address

Tadworth

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Pfizer Ltd
Sign up free

Contracts awarded to Pfizer Ltd

The contracts that Pfizer Ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 2 months ago

NP41125 Immunosuppressant Medicines

Supply of immunosuppressant medicines to NHS Scotland.

£3,437,024
Award

Published 2 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 16

Generic, Branded Generic & Proprietary Medicinal Products - Group 16 (5762100)

£36,914,657
Award

Published 2 months ago

NP30925 Psychiatry and Neurology Medicines

Supply of psychiatry and neurology medicines to NHS Scotland.

£7,031,939
Award

Published 2 months ago

NHS National Generic Pharmaceuticals Wave 15b

NHS National Pharmaceuticals Generic Products – Wave 15b Offer reference number: CM/PHG/23/5698 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5698/01 – Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months) NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months) LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months) CM/PHG/23/5698/02 – Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months) CM/PHG/23/5698/03 – Hospital Only (Housekeeping) Products DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months) DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months) DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months)

£147
Award

Published 3 months ago

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

£4,108,145,000 Bids close: 6 months ago
Award

Published 3 months ago

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

£24

Contacts

+44 7471112086

[email protected]

Statistics (1 Year)

Contracts Won

Total Won

£607,735,831

Average Win

£50,644,653

Pfizer Ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Pfizer Ltd

NP41125 Immunosuppressant Medicines

Generic, Branded Generic & Proprietary Medicinal Products - Group 16

NP30925 Psychiatry and Neurology Medicines

NHS National Generic Pharmaceuticals Wave 15b

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win